Skip to main content

Advertisement

SpringerLink
Log in

Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The goal of a cancer prevention program is to improve the mortality rates of patients. No risk-reduction strategy is proven to reduce mortality rates of women at increased risk for ovarian cancer. Methods of ovarian cancer surveillance are unproven in highrisk women. According to some studies, the use of oral contraceptives in high-risk women reduces ovarian cancer risk. Prophylactic salpingo-oophorectomy is the most effective method of cancer risk reduction in women at high risk for ovarian cancer. However, women who undergo prophylactic salpingo-oophorectomy remain at risk for primary peritoneal cancer. A minority of women with BRCA1 and BRCA2 mutations are diagnosed with occult cancer at the time of surgical prophylaxis. Surgical prophylaxis should include complete removal of the fallopian tubes and ovaries, procurement of peritoneal cytology, and thorough evaluation of the tubes and ovaries by an expert pathologist. Beginning at age 30 years, women with BRCA1 and BRCA2 germline mutations should have an annual or semiannual screening, consisting of serum CA-125 measurement and transvaginal ultrasound, until the completion of childbearing. After the completion of childbearing and by age 40 years, women should undergo prophylactic salpingo-oophorectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brody LC, Biesecker BB: Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 1998, 77:208–226.

    Article  CAS  Google Scholar 

  2. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993, 71:677–685.

    Article  PubMed  CAS  Google Scholar 

  3. Aarnio M, Sankila R, Pukkala E, et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214–218.

    Article  PubMed  CAS  Google Scholar 

  4. Aarnio M, Mecklin JP, Aaltonen LA, et al.: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64:430–433.

    Article  PubMed  CAS  Google Scholar 

  5. Modan B, Hartge P, Hirsh-Yechezkel G, et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:235–240. A population study of Israeli women with ovarian cancer reporting that parity reduced ovarian cancer risk in women with BRCA1 and BRCA2 mutations.

    Article  PubMed  CAS  Google Scholar 

  6. Trimble EL: The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994, 55:S1-S3.

    Article  PubMed  CAS  Google Scholar 

  7. Bourne T, Campbell S, Reynolds K, et al.: The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994, 52:379–385.

    Article  PubMed  CAS  Google Scholar 

  8. Dorum A, Heimdal K, Lovslett K, et al.: Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999, 78:906–911.

    Article  PubMed  CAS  Google Scholar 

  9. van Nagell JR Jr, DePriest PD, Reedy MB, et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350–356.

    Article  PubMed  Google Scholar 

  10. Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277:997–1003.

    Article  PubMed  CAS  Google Scholar 

  11. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al.: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999, 180:917–928. A study describing the occurrence of advanced stage peritoneal cancer among high-risk women being screened for ovarian cancer, revealing a limitation of screening in women at risk for familial ovarian cancer.

    Article  PubMed  CAS  Google Scholar 

  12. Jacobs I, Davies AP, Bridges J, et al.: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993, 306:1030–1034.

    Article  PubMed  CAS  Google Scholar 

  13. Erlick Robinson G, Rosen BP, Bradley LN, et al.: Psychological impact of screening for familial ovarian cancer: reactions to initial assessment. Gynecol Oncol 1997, 65:197–205.

    Article  Google Scholar 

  14. Weiss NS, Lyon JL, Liff JM, et al.: Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981, 28:669–671.

    Article  PubMed  CAS  Google Scholar 

  15. Willett WC, Bain C, Hennekens CH, et al.: Oral contraceptives and risk of ovarian cancer. Cancer 1981, 48:1684–1687.

    Article  PubMed  CAS  Google Scholar 

  16. Rosenberg L, Palmer JR, Zauber AG, et al.: A casecontrol study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994, 139:654–661.

    PubMed  CAS  Google Scholar 

  17. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone study.JAMA 1983, 249:1596-1599.

  18. Zatyka M: The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987, 316:650–655.

    Article  Google Scholar 

  19. Vessey MP, Painter R: Endometrial and ovarian cancer and oral contraceptives: findings in a large cohort study. Br J Cancer 1995, 71:1340–1342.

    PubMed  CAS  Google Scholar 

  20. Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998, 339:424–428.

    Article  PubMed  CAS  Google Scholar 

  21. Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case control study. Lancet 2001, 357:1467–1470. A case control study showing a reduction in risk for ovarian cancer from use of oral contraceptives among BRCA mutation carriers and from bilateral tubal ligation in BRCA1 mutation carriers.

    Article  PubMed  CAS  Google Scholar 

  22. Kemp GM, Hsiu JG, Andrews MC: Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol 1992, 47:395–397.

    Article  PubMed  CAS  Google Scholar 

  23. Piver MS, Jishi MF, Tsukada Y, et al.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993, 71:2751–2755.

    Article  PubMed  CAS  Google Scholar 

  24. Schorge JO, Muto MG, Welch WR, et al.: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998, 90:841–845.

    Article  PubMed  CAS  Google Scholar 

  25. Kauff ND, Satagopan JM, Robson ME, et al.: Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609–1615.

    Article  PubMed  Google Scholar 

  26. Zhuang SH, Leonard GD, Swain SM: Oophorectomy in carriers of BRCA mutations. N Engl J Med 2002, 347:1037–1040.

    Article  PubMed  Google Scholar 

  27. Whitfield GA: Oophorectomy in carriers of BRCA mutations. N Engl J Med 2002, 347:1037–1040.

    Article  PubMed  Google Scholar 

  28. Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616–1622. A landmark study indicating the strong effect of prophylactic oophorectomy on reducing the risk of ovarian and breast cancer in women with BRCA1 and BRCA2 mutations.

    Article  PubMed  Google Scholar 

  29. Goshen R, Chu W, Elit L, et al.: Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000, 79:477–481.

    Article  PubMed  CAS  Google Scholar 

  30. Levine DA, Lin O, Barakat RR, et al.: Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001, 80:395–398.

    Article  PubMed  CAS  Google Scholar 

  31. Dunlop MG, Farrington SM, Carothers AD, et al.: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997, 6:105–110.

    Article  PubMed  CAS  Google Scholar 

  32. Leeper K, Garcia R, Swisher E, et al.: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87:52–56. This study identified occult cancers of the fallopian tube, peritoneum, and ovary in 17% of high-risk women undergoing prophylactic surgery.

    Article  PubMed  Google Scholar 

  33. Lu KH, Garber JE, Cramer DW, et al.: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000, 18:2728–2732. Describes the identification of occult cancers in 12% of women with BRCA1 and BRCA2 mutations undergoing prophylactic surgery.

    PubMed  CAS  Google Scholar 

  34. Colgan TJ, Boerner SL, Murphy J, et al.: Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002, 85:397–403.

    Article  PubMed  Google Scholar 

  35. Paley PJ, Swisher EM, Garcia RL, et al.: Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001, 80:176–180.

    Article  PubMed  CAS  Google Scholar 

  36. Agoff SN, Mendelin JE, Grieco VS, et al.: Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002, 26:171–178.

    Article  PubMed  Google Scholar 

  37. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.JAMA 2002, 288:321-333.

  38. Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91:1475–1479.

    Article  PubMed  CAS  Google Scholar 

  39. Grann VR, Panageas KS, Whang W, et al.: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998, 16:979–985.

    PubMed  CAS  Google Scholar 

  40. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al.: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 2002, 20:2092–2100.

    Article  PubMed  Google Scholar 

  41. Hankinson SE, Hunter DJ, Colditz GA, et al.: Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993, 270:2813–2818.

    Article  PubMed  CAS  Google Scholar 

  42. Cornelison TL, Natarajan N, Piver MS, et al.: Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 1997, 21:1–6.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific, Box 356460, 98195, Seattle, WA, USA

    Elizabeth Swisher MD

Authors
  1. Elizabeth Swisher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swisher, E. Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. Curr. Treat. Options in Oncol. 4, 105–110 (2003). https://doi.org/10.1007/s11864-003-0011-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0011-1

Keywords

Search

Navigation